Trial Profile
A Double-blind, Parallel Group, Randomized, Placebo Controlled Sleep Laboratory Study of Efficacy and Safety of Neu-P11 in Insomnia Patients Aged 18-80.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2018
Price :
$35
*
At a glance
- Drugs Piromelatine (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- 18 Feb 2013 Results will be presented at the 27th Annual Meeting of the Associated Professional Sleep Societies (APSS), according to a Neurim Pharmaceuticals media release.
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.